In patients with triple-negative and HER2-positive BC receiving neoadjuvant chemotherapy, DL-assisted analysis showed higher sTIL scores in responders and a correlation between high sTIL levels (sTIL ≥ 50) and chemotherapeutic response. The gene discussed is ERBB2; the disease is breast cancer.